Clinical application of methylated PAX1 in cervical cancer screening and prognosis assessment
Objective To explore the clinical application of methylated PAX1 in cervical cancer screening and prognosis assessment.Method The study involved 150 women treated between January and December 2021,and collected cervical exfoliated cells from patients with exfoliated cervical cells.The study used a variety of testing techniques,including PAX1 gene,methylation,thin layer cytology,high-risk HPV virus and HPV16/18 testing.Colposcopic biopsy of positive patients was used as the gold standard to compare different de-tection methods in cervical exfoliated cells.Results The methylation sensitivity and specificity of PAX1 gene were 81.3%and 96.6%,respectively.Among the four kinds of detection,PAX1 had the highest specificity of 96.63%in cytology and 17%～70%in hrHPV.The sensitivity of ASCUS+ was 94.7%,which was significantly higher than that of PAX1 gene methylation detection(P<0.05),but the speci-ficity of ASCUS+ was 18.0%,which was significantly lower than that of PAX1 gene methylation detection(P<0.001).Conclusion The combination of cytology and PAX1 gene methylation technology can better prevent cervical cancer and reduce anxiety in young patients.
Methylated PAX1Cervical cancer screeningPrognosis assessmentClinical application
万方数据
维普
